Clinical Trial Update: Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity [Phase 4]

View source ↗

Summary

Phase 4 trial update for ACULAR in inhibiting proliferative retinopathy in prematurity; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blindness
• Retinal Detachment
• Retinopathy of Prematurity

Drugs mentioned

• ACULAR (Ketorolac tromethamine)

Snippet

Sponsor: University of South Alabama | Conditions: Retinopathy of Prematurity, Retinal Detachment | Phase 4 | Status: TERMINATED | Results posted: 2020-12-08